0 75

Cited 2 times in

Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer

 Hyung Soon Park  ;  Joohyuk Sohn  ;  Seung Il Kim  ;  Seho Park  ;  Hyung Seok Park  ;  Seul Ghi Gho  ;  Hyun Cheol Chung  ;  Soonmyung Paik  ;  Gun Min Kim 
 Breast Cancer Research and Treatment, Vol.163(2) : 255-262, 2017 
Journal Title
 Breast Cancer Research and Treatment 
Issue Date
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Bone Neoplasms/drug therapy ; Bone Neoplasms/metabolism* ; Bone Neoplasms/mortality ; Bone Neoplasms/secondary ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism* ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Multivariate Analysis ; Paclitaxel/administration & dosage ; Proportional Hazards Models ; Receptor, ErbB-2/metabolism* ; Retrospective Studies ; Taxoids/administration & dosage uzumab/administration & dosage Treatment Outcome
Durable response ; Hormone receptor status ; Landmark analysis ; Trastuzumab
PURPOSE: Trastuzumab-based treatment is the standard care for patients with HER2+ metastatic breast cancer (MBC). About 10% of HER2+ MBC showed a long-term durable response (progression-free survival, PFS > 3 years) to trastuzumab-based therapy. The aim of this study is to identify clinico-pathologic factors for a durable response to trastuzumab-based therapy in HER2-positive MBC. METHODS: In the Yonsei Breast Cancer MBC Database, we identified 1218 MBC patients who were diagnosed from 2006 to 2015. Among them, 294 had HER2+ disease, and 153 received trastuzumab plus taxane chemotherapy as first-line treatment. Clinico-pathologic factors, such as hormone receptor (HR) status and metastatic sites, were reviewed. To evaluate a durable response, landmark analysis was performed. RESULTS: The median follow-up time was 28 months (95% CI 4.4-83.0 months). Of 153 HER2+ patients, there were 73 HR- patients (47.7%), and bone was the most common metastatic site. The median PFS and overall survival (OS) were 12 and 39 months, respectively. HR- patients showed a tendency toward longer PFS (median, 13 vs. 11 months, P = 0.160) compared with HR+ patients. Patients with non-visceral metastases had longer median PFS and OS than those with visceral disease (median PFS, 15 vs. 11 months, P = 0.012; median OS, 75 vs. 34 months, P = 0.03). Landmark analysis at 9 months suggested that the PFS of HR- patients was significantly longer than that of HR+ patients (median, 19 vs. 9 months, P = 0.008). CONCLUSIONS: Among patients with HER2+ MBC, HR status is a possible predictive biomarker of a durable response to trastuzumab-based therapy.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
Yonsei Authors
김건민(Kim, Gun Min) ORCID logo https://orcid.org/0000-0001-9167-8682
김승일(Kim, Seung Il)
박세호(Park, Se Ho) ORCID logo https://orcid.org/0000-0001-8089-2755
박형석(Park, Hyung Seok) ORCID logo https://orcid.org/0000-0001-5322-6036
박형순(Park, Hyung Soon)
백순명(Paik, Soon Myung) ORCID logo https://orcid.org/0000-0001-9688-6480
손주혁(Sohn, Joo Hyuk) ORCID logo https://orcid.org/0000-0002-2303-2764
정현철(Chung, Hyun Cheol) ORCID logo https://orcid.org/0000-0002-0920-9471
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.